ImmuPharma plc (LON:IMM – Get Free Report)’s share price was down 17.8% during mid-day trading on Thursday . The stock traded as low as GBX 3.70 and last traded at GBX 3.70. 1,186,007 shares traded hands during trading, a decline of 55% from the average daily volume of 2,650,268 shares. The stock had previously closed at GBX 4.50.
ImmuPharma Stock Performance
The firm has a fifty day simple moving average of GBX 4.17 and a 200 day simple moving average of GBX 5.27. The company has a market cap of £22.34 million, a PE ratio of -9.68 and a beta of 3.02.
ImmuPharma (LON:IMM – Get Free Report) last issued its earnings results on Wednesday, May 27th. The company reported GBX (0.37) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 353.21%. As a group, equities analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- MarketBeat Week in Review – 07/27- 07/31
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
